TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

GlobeNewswire Inc. Logo GlobeNewswire Inc. By In8Bio, Inc.
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

IN8bio announced The Ohio State University as a new clinical site for its Phase 1 trial of INB-100, a gamma-delta T cell therapy for leukemia patients undergoing stem cell transplantation. The trial aims to explore strategies for reducing graft-versus-host disease and relapse risks.

Insights
VNOpN   neutral

Standard dividend declaration with no significant positive or negative indicators, routine financial reporting


INAB   positive

Company is expanding clinical trial sites, demonstrating progress in developing innovative cancer therapy with promising early results and long-term patient remissions